INTRODUCTION
We describe a case of a 66-year-old man with a history of chronic kidney disease and recurrent nephrolithiasis with bilateral stents who had positive concurrent urine and blood cultures for MDR PSA, susceptible only to amikacin and colistin. Due to the MDR phenotype and his underlying kidney disease, a renally adjusted C/T monotherapy regimen was initiated for his bloodstream infection (BSI).
CASE PRESENTATION
A 66-year-old Caucasian man with past medical history significant for morbid obesity, chronic kidney disease (baseline Cr 3.0-3.4 mg/dl; estimated creatinine clearance CrCl *35 ml/ min; not on dialysis), right-sided heart failure, hypothyroidism, recurrent nephrolithiasis and urinary tract infections with multiple urologic procedures, was admitted to the hospital with complaints of fevers and chills. Blood cultures taken on admission returned positive for Proteus mirabilis. Initial urine cultures revealed P. mirabilis and Klebsiella pneumoniae and a repeat urine culture a day later revealed P. mirabilis along with an MDR PSA. CT preformed of the abdomen showed an obstructing 7 mm calculus within the proximal right ureter, near the right ureteropelvic junction. Right hydronephrosis and additional calculi within the right renal pelvis were also noted. The patient was treated with ceftriaxone and underwent cystoscopy, 
METHODS AND RESULTS
The patient had received 46 doses of C/T (well after the fifth dose when steady state is expected to be achieved) before serum drug levels were checked. Blood was obtained at the end of infusion (1 h) and at 3, 5 and 8 h for drug concentration determination using a validated high-performance liquid chromatography method at the Center for Anti-Infective
Research and Development, Hartford Hospital, Hartford [7] . Total C/T serum concentrations at 1, 3, 5 and 8 after the start of the infusion were 41.4/6.9, 36.8/5.1, 28.7/3.2 and 21.9/2.8 lg/ml, respectively. Using a non-compartmental pharmacokinetic approach, the area under the concentration-time curve (AUC) over the dosing interval was calculated to be 473 lg h/ ml for C, while its half-life was estimated to be 7.4 h. Importantly, the recommended renal adjusted dose produced concentrations of C that were maintained above the MIC of the infecting PSA as well as the susceptibility breakpoint of 4 lg/ml through the entire dosing interval. As a result of the low protein Patients with severe renal impairment (CrCl \30 ml/min) were excluded from the study [6].
Our patient falls into this latter category, and while there was no guidance as to effective dosing from the literature, manufacturer recommendations were used to guide dosing [1] . Importantly, the pharmacokinetic data derived from this case confirm the adequacy of the manufacturers' defined renal dose in a bacteremic patient with multiple co-morbid conditions as the concentrations were maintained well above the susceptibility breakpoint value of 4 lg/ml. Moreover, the overall exposure as defined by the AUC for this dosing regimen was quite similar to dose-adjusted exposures previously defined in non-infected renal patients [8] .
Rates of infection due to MDR PSA are increasing, leading to increased mortality and healthcare costs in addition to treatment challenges for clinicians [9] [10] [11] . Often, very few therapeutic options exist and patient allergies and intolerance to antimicrobials can limit these options even further. Emergence of resistance occurring during treatment of initially susceptible infections also complicates management of these infections. Consideration should be given to the pharmacokinetics and MDR pathogen, the exposure obtained in this patient was also similar to that observed by VanScoy and colleagues as being required to prevent the amplification of PSA-drug-resistant bacterial subpopulations using a hollow-fiber infection model [13] .
Though the controversy of combination therapy versus monotherapy has not fully been elucidated, therapy for severe infections with two antipseudomonal agents are often empirically started to avoid inadequate therapy or treatment failure [14] . Multi-drug resistance has been shown to be associated with inappropriate empirical antibiotic therapy, and although inappropriate initial coverage for PSA BSI has been shown to be an independent risk factor for mortality, there is some conflicting evidence in the literature [15] [16] [17] [18] [19] . Successful regimens for MDR PSA infections, mainly described in the form of case reports and retrospective reviews, have included continuous-infusion meropenem, parenteral colistin therapy with and without the addition of rifampin, and combination therapy with antipseudomonal beta-lactams plus aminoglycosides [15, 16, 20] . Double antipseudomonal beta-lactam therapy with or without the addition of an aminoglycoside has been shown in vitro to have synergy effects despite resistance to one or more of these agents, though clinical data are lacking [21, 22] .
In 
